Cargando…

Idelalisib: a rare cause of enterocolitis

Idelalisib is an oral, phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, approved by FDA since July 2014 for the treatment of relapsed follicular B-cell non-Hodgkin lymphoma. Data from three phases of the study involving idelalisib demonstrate diarrhea (47%) to be the common adverse effect. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Balagoni, Harika, Chaudhari, Dhara, Reddy, Chakradhar, Young, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805750/
https://www.ncbi.nlm.nih.gov/pubmed/27065742
http://dx.doi.org/10.20524/aog.2016.0022

Ejemplares similares